石四药集团盐酸齐拉西酮原料药获国家药监局注册批准

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Ziprasidone Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Ziprasidone Hydrochloride, being the second generation of antipsychotic drug, is a novel, atypical and broad-spectrum antipsychotics mainly used for the treatment of schizophrenia.

This approval further enhances the supporting capabilities of the Group’s bulk pharmaceuticals in the psychotropic and neurological fields, and enriches the Group’s product portfolio of Highly Potent Active Pharmaceutical Ingredients (HPAPI).

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board Chow Hing Yeung Executive Director and Company Secretary Hong Kong, 7 August 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.